CARDINAL: A Phase 1 Study of TERN-701, a Novel, Investigational Allosteric BCR::ABL1 Inhibitor for Patients with Previously Treated CML

admin | November 24, 2025

CARDINAL: A Phase 1 Study of TERN-701, a Novel, Investigational Allosteric BCR::ABL1 Inhibitor for Patients with Previously Treated CML

Recent Posts

July 26, 2023

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress for Preclinical Data on Novel Allosteric BCR-Abl Inhibitor Tern-701

May 17, 2023

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Popular Tags

Architecture

Design Interior

Blog Post

CARDINAL: A Phase 1 Study of TERN-701, a Novel, Investigational Allosteric BCR::ABL1 Inhibitor for Patients with Previously Treated CML

Recent Posts

Topic

Popular Tags